IGC Pharma, Inc.
IGC
$0.29
$0.000.32%
AMEX
| 06/30/2026 | 03/31/2026 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -6.51% | 24.95% | -5.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -6.51% | 24.95% | -5.50% |
| Cost of Revenue | -- | -- | 14.86% | 70.31% | 6.54% |
| Gross Profit | -- | -- | -23.16% | -4.84% | -15.55% |
| SG&A Expenses | -- | -- | -41.90% | -49.58% | -40.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -19.53% | -31.44% | -26.35% |
| Operating Income | -- | -- | 21.07% | 36.99% | 29.02% |
| Income Before Tax | -- | -- | 48.71% | 52.32% | 45.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 48.71% | 52.32% | 45.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 48.71% | 52.32% | 45.22% |
| EBIT | -- | -- | 21.07% | 36.99% | 29.02% |
| EBITDA | -- | -- | 21.84% | 38.88% | 30.70% |
| EPS Basic | -- | -- | 58.49% | 61.74% | 56.69% |
| Normalized Basic EPS | -- | -- | 48.53% | 53.95% | 46.46% |
| EPS Diluted | -- | -- | 58.49% | 61.74% | 56.69% |
| Normalized Diluted EPS | -- | -- | 48.53% | 53.95% | 46.46% |
| Average Basic Shares Outstanding | -- | -- | 19.51% | 24.01% | 30.04% |
| Average Diluted Shares Outstanding | -- | -- | 19.51% | 24.01% | 30.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |